Prospective assessment of circulating tumor DNA in patients with metastatic uveal melanoma treated with tebentafusp

Manuel Rodrigues, Toulsie Ramtohul, Aurore Rampanou, José Luis Sandoval, Alexandre Houy, Vincent Servois, Léah Mailly-Giacchetti, Gaelle Pierron, Anne Vincent-Salomon, Nathalie Cassoux, Pascale Mariani, Caroline Dutriaux, Marc Pracht, Thomas Ryckewaert, Jean-Emmanuel Kurtz, Sergio Roman-Roman, Sophie Piperno-Neumann, François-Clément Bidard, Marc-Henri Stern () and Shufang Renault ()
Additional contact information
Manuel Rodrigues: Institut Curie
Toulsie Ramtohul: PSL Research University
Aurore Rampanou: Institut Curie
José Luis Sandoval: Institut Curie
Alexandre Houy: PSL Research University
Vincent Servois: PSL Research University
Léah Mailly-Giacchetti: PSL Research University
Gaelle Pierron: PSL Research University
Anne Vincent-Salomon: PSL Research University
Nathalie Cassoux: PSL Research University
Pascale Mariani: PSL Research University
Caroline Dutriaux: Hôpital Saint André Centre Hospitalier Universitaire
Marc Pracht: Centre Eugène Marquis
Thomas Ryckewaert: Oscar Lambret Center
Jean-Emmanuel Kurtz: ICANS
Sergio Roman-Roman: PSL Research University
Sophie Piperno-Neumann: Institut Curie
François-Clément Bidard: Institut Curie
Marc-Henri Stern: PSL Research University
Shufang Renault: Institut Curie

Nature Communications, 2024, vol. 15, issue 1, 1-10

Abstract: Abstract Tebentafusp, a bispecific immune therapy, is the only drug that demonstrated an overall survival benefit in patients with metastatic uveal melanoma (MUM). Circulating tumor DNA (ctDNA) has emerged as a potential prognostic and predictive marker in the phase 3 IMCgp100-202 trial using multiplex PCR-based next-generation sequencing (NGS). In this study (NCT02866149), ctDNA dynamics were assessed using droplet digital PCR (ddPCR) in 69 MUM patients undergoing tebentafusp treatment. Notably, 61% of patients exhibited detectable ctDNA before treatment initiation, which was associated with shorter overall survival (median 12.9 months versus 40.5 months for patients with undetectable ctDNA; p

Date: 2024
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-024-53145-0 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-53145-0

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-024-53145-0

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().